NEXT MASSIVE PENNY STOCK At $1 - ZOM Stock BREAKING NEWS - 5X GROWTH (Time Sensitive)
Like And Subscribe!
There is a penny stock worth just 1 dollars per share right now with A UNIQUE BUSINESS MODEL and THE POTENTIAL TO GO EVEN 5X IN SHARE PRICE. They are Zomedica ticker symbol ZOM and have gone up ALOT IN SHARE PRICE recently and ARE GOING UP TODAY, Wednesday based on some BIG NEWS. BUT What do they actually do, why are they going up so much and is it too late to buy some stock right now? Let’s go through all of this in this video, so stay tuned guys!
Firstly let’s go through what Zomedica actually does! Well in their own words, Zomedica is an animal health company creating products for companion animals (canine and feline) by focusing on the unmet needs of clinical veterinarians and emphasizing patient health and practice health.
What is so interesting about Zomedica is that THEY ARE RIGHT NOW WORTH more than 500 million dollars but still haven’t made any revenue. But why do analysts think that they COULD DOUBLE TRIPLE or even 5x in share if they haven’t even sold anything yet? Well because they are just about to launch their FIRST MAJOR PRODUCT. A unique diagnostics tech platform called Truforma. Once this platform debuts, MANY EXPERTS THINK THAT IT WILL DISTRUPT the entire veterinary diagnostics market AND IN TURN MASSIVELY BOOST THE REVENUE of Zomedica.
This one single product TRUFORMA takes the complex, timely and costly process of diagnosing various different diseases and makes it simple, cheap and quick. So there really is NO REASON FOR THIS NOT TO BE in the hands of every veterinarian.
Instead of taking days and hundreds of dollars by sending a stool or blood sample to a laboratory, all you need to do with this product is to get a sample OF THE PET IN THE CLINIC, let the machine use its NEW, UNIQUE TECHNOLOGY to within 20 minutes return high quality test results for just a few bucks.
And according to different experts there really is no catch, IT DOES SEEM LIKE TRUFORMA will be very disruptive and do great things in THIS MARKET. And guys that is why Zomedica went up so much on this announcement, there is crazy amounts of money to be made if this goes out to all veterinarians all over the country and maybe beyond.
But why IS IT STILL UNDERVALUED IN MY OPINION, even with the over 500 million dollar market cap it has right now? We just need to look at a couple of things in order to understand why.
Firstly the TRUFORMA platform which will only be used for the diagnosis of thyroid disease in dogs and casts, and adrenal disease in dogs, IS USING A TECHNOLOGY that is very scalable and repeatable. Zomedica could easily move on to things like Renal disease or Diabetes over the next few years, without really costing too much money.
So this whole platform REALLY HAS THE POTENTIAL to turn into an all-in-one, in-clinic diagnostic testing platform that takes a multi-day, expensive testing process, and shrinks it into a 20-minute, super cheap testing process. Right now there are 35 000 vet clinics in the US that are running in-clinic chemistry so this could first go TO ALL THOSE CLINICS, AND IF JUST THAT HAPPENS that would already warrant a much higher share price in my opinion.
GUYS ONE MIGHT NOT EXPECT IT BUT THE US VETERINARY DIAGNOSTICS MARKET IS MASSIVE. It was measured at $2.8 billion in 2018 and It’s consistently growing at 10% per year. By 2025 that would mean MORE THAN 5 BILLION DOLLARS. Assuming that TRUFORMA and in turn Zomedica can have just 5% of the market shares here that would imply 250 million dollars in revenue.
And with other Veterinarian medicine stocks such as Idexx and Zoetis usually having a share price that is SEVEN times higher than their yearly revenues, that would mean that Zomedicas MARKET CAP COULD GO TO 1.75 BILLION DOLLARS and in turn leading to a share price of over 3 dollars.